On June 25th, Johnson & Johnson (JNJ.US) announced that the application for the listing of teclistamab injection has been approved by the National Medical Products Administration (NMPA) of China. Teclistamab is a ready-to-use, subcutaneously injected bispecific antibody therapy targeting BCMA and CD3. The indication approved for this drug this time is for monotherapy in adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior therapies. According to Johnson & Johnson's press release, teclistamab has a high response rate in patients with relapsed or refractory multiple myeloma who have received at least three prior therapies, with a overall response rate (ORR) of 76.9% among Chinese patients who benefit more.

Multiple myeloma is the second most common malignant tumor in the hematological system. Currently, it is still an incurable blood cancer, and almost all patients will experience relapse and require subsequent treatment. As the disease progresses, the invasiveness of each relapse increases, while the duration of remission obtained by new therapies gradually shortens.

According to publicly available information, teclistamab is a ready-to-use, subcutaneously injected bispecific antibody targeting B-cell maturation antigen (BCMA) and the T lymphocyte surface CD3 receptor. It recruits CD3-positive T cells to the vicinity of myeloma cells expressing BCMA and activates T cells to attack tumor cells. Previously, the product has received breakthrough therapy designation for the treatment of multiple myeloma from the U.S. FDA and has been granted priority medicinal product qualification (PRIME) by the European Medicines Agency (EMA).